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Summary Statement: 
Cavities	in	retinoblastoma	tumors	can	evolve	on	systemic	chemotherapy.	The	detection	of	
cavities	confer	stability	and	aggressive	consolidation	therapy	is	not	required.		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Structured Abstract 
Purpose: 
To assess the role of consolidating adjuvant therapy for cavitary retinoblastoma (CRs) and to 
understand if there is any phenotype- genotype correlation. 
Methods: 
Patients with retinoblastomas having ophthalmoscopically visible cavities between 2004 and 
2014 in whom 4-6 cycles of systemic chemotherapy were given. 
Results 
Eighteen eyes of 17 patients displayed CRs. This represented 6.8% of 250 patients. Mean age 
at diagnosis was 13 months; 5 unilateral (29%) and 12 bilateral (71%). The mean (median, 
range) number of retinoblastoma tumors per eye was 2 (2; 1–6). The number of cavities per 
tumor was 3 (2, 1–6). Intra-tumoral cavities were seen in the superficial portion of the tumor 
in 10 eyes (55%). The cavities became visible in 8 eyes (44%) and collapsed in 8 eyes (44%). 
Two eyes required enucleation due to relapse in non-cavitary tumors. Germline mutations 
were detected in 14 patients (82%) of whom, four demonstrated mosaicism (29%). The mean 
follow-up period was 40 (35, 6–120) months.  
Conclusion 
CRs can be detected following systemic chemotherapy with cavities becoming visible after 
mean 2 cycles of chemotherapy. They remain stable and do not require aggressive adjuvant 
therapy. There was no evident phenotype-genotype correlation with mosaicism noted in 29%. 
 
Abbreviations: cavitary retinoblastoma (CR), retinoblastoma (Rb). 
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Introduction 1	
Retinoblastoma (Rb) is a life-threatening intraocular malignancy of childhood. Generally, the 2	
tumors manifest as a dome-shaped, solid white retinal mass with prominent intrinsic and 3	
feeder vessels. Rarely, ophthalmoscopically visible lucent cavities can occur. 1, 2  4	
These cavitary spaces appear hollow on ultrasonography and hypofluorescent on 5	
angiography.3 Rb tumors are known to respond to chemotherapy4, 5 often with resolution of 6	
retinal detachment and shrinkage of the tumor, but relapse can occur after treatment. The few 7	
previous reports on cavitary retinoblastoma (CR) have described its relative chemoresistant 8	
and radioresistant features.2,6 Although the tumor size does not reduce dramatically, they tend 9	
not to relapse.7 Currently, it is common practice to apply consolidation laser to 10	
retinoblastoma tumors during systemic chemotherapy.4,8,9  It has been suggested that 11	
prolonged adjuvant therapy is not necessary in CR.7  12	
Histopathologically, the cavitary spaces represent areas of photoreceptor differentiation in the 13	
area adjacent to the cavitations.10 This may explain the perception of muted response to 14	
therapy and low risk of reactivation. 15	
Despite these interesting findings, there is little in the literature on the genotype – phenotype 16	
correlation of CR. In this report therefore, we seek to understand further the clinical 17	
phenotype of CR and its natural history, correlate this to genetic findings, and to examine the 18	
need for adjuvant therapy once CR occurs.  19	
SUBJECTS 20	
We reviewed the medical records of 250 newly diagnosed patients with retinoblastoma that 21	
were managed at the Retinoblastoma Unit at the Royal London Hospital from January 1, 2004, 22	
through Dec 31, 2014. This study was approved by Barts Health Clinical Effectiveness Unit 23	
(Number 5963), within tenets of the Declaration of Helsinki. Patients with the diagnosis of 24	
cavitary retinoblastoma and treatment with systemic chemotherapy were selected for analysis. 25	
This was a retrospective, nonrandomized, non-comparative interventional case series.  26	
METHODS 27	
Information collected included demographic details, clinical findings, treatments, and outcome 28	
(relapse, globe salvage metastasis and morality). Each patient underwent evaluation for age at 29	
diagnosis (in months), sex (male or female), race (White, European or South Asian). Results 30	
of genetic testing (hereditary or non-hereditary) were also recorded.11 A comprehensive ocular 31	
examination under anaesthesia was performed with assessment for laterality (unilateral or 32	
bilateral), International Intraocular Retinoblastoma Classification,12 intraocular pressure 33	
(measured by means of Perkins tonometry within the first few minutes of general anaesthesia); 34	
status of the anterior chamber, iris, ciliary body, optic nerve, choroid, retina, and vitreous; total 35	
number of tumors per eye; total number of cavitary tumors per eye; location of cavitary tumor; 36	
total number of cavities within each tumor and location of cavities within each tumor. The 37	
presence of associated vitreous seeds (present or absent), percentage of retinal detachment (0-38	
100%), and presence of subretinal tumor seeds (present or absent) was also recorded.  39	
 40	
All patients received four to six cycles of systemic intravenous chemotherapy with vincristine 41	
(1.5 mg/m2) etoposide (300 mg/m2) and carboplatin (600 mg/m2) which were delivered at 42	
three weekly intervals. Trans-pupillary Thermo-Therapy (TTT) was done using Diode Laser 43	
(810nm), median intensity used was 350mW (250mW- 500mW) for 9 seconds, and the spot 44	
size was 1.2mm.  45	
 46	
The diagnosis of CR was based on fundus photography and indirect ophthalmoscopy either at 47	
presentation or after chemotherapy. Fundus photographs (RetCam) were compared on first 48	
and last follow-up visits. Each cavitary tumor was assessed for tumor regression pattern, and 49	
percentage of cavities collapsed. Patient mortality and metastases at the last follow-up 50	
examination was also recorded.  51	
 52	
RESULTS 53	
Out of 250 (167 unilateral – 67%, and 83 bilateral – 33%) patients with newly diagnosed 54	
retinoblastoma, 17 patients (6.8%) had cavitary retinoblastoma at presentation. One child had 55	
cavitary tumors in both eyes. Hence, cavitary tumors were found in 18 eyes of 17 patients, (5 56	
unilateral-29% and 12 bilateral -71% patients). The mean patient age at presentation was 14 57	
months (median, 14; range 2 weeks-24months). Ethnicity of the patients was White British 58	
11 patients (64%), White European 4 patients (24%) and South Asian (2 patients, 12%). 59	
 60	
In 10 eyes (56%)  CR was evident at initial presentation in treatment naive eyes and in 8 eyes 61	
(44%) CR was found after two cycles of systemic chemotherapy. The mean (median, range) 62	
number of retinoblastoma tumors per eye was 2 (2; 1–6) and number of cavitary 63	
retinoblastomas per eye was 1 (1; 1-2). The number of cavities per tumor was 3 (3, 1–6). 64	
Associated features were subretinal fluid in 2 eyes (11%), vitreous seeds in 1 eye (5%) and 65	
subretinal seeds in 2 eyes (11%). Intra-tumoral cavities were seen in the superficial portion of 66	
the tumor in 10 eyes (55%) at presentation. The epicenter of the quadrant of the CR relative 67	
to the optic disc was superior to the optic disc in 2 eyes (11%), inferior in 3 eyes (17%) and 68	
nasal to the disc in 3 eyes (17%).Cavitary tumors occurred in the macula (temporal to the 69	
disc) in 10 eyes (55%), in 7 of which the foveola was affected by the cavity. According to the 70	
International Classification of Retinoblastoma, 12 there were no eyes in Group A, 5 eyes 71	
(28%) in group B, 3 eyes (17%) in group C, 9 eyes (50%) in group D, and 1 eye (5%) in 72	
group E. Germline (hereditary) mutations were detected in 14 patients (82%) of whom 4 73	
demonstrated mosaicism (29%). 74	
TREATMENT 75	
The cavities became visible ophthalmoscopically in 8 eyes (44%) after an average 2 cycles of 76	
systemic chemotherapy (FIG 1 and 2). Cavitary tumors were treated with laser transpupillary 77	
thermotherapy in 3 eyes in an attempt to prevent future relapse (17%) while in 15 eyes 78	
cavitary tumors remained in remission without further direct treatment to that tumor (83%). 79	
Other non-cavitary retinoblastoma tumors in eyes that also harboured CR relapsed in 9 eyes 80	
(50%), requiring adjuvant treatments (transpupillary thermotherapy, cryotherapy, 81	
intraophthalmic artery Melphalan chemotherapy, intravitreal Melphalan, brachytherapy, 82	
external beam radiotherapy). In 8 eyes (44%) no adjuvant therapy was given to either 83	
cavitary or non-cavitary tumors. Type 3 regression was seen in 10 eyes (56%) mixed type-84	
partially calcified, type 2 in 7 eyes (38%) completely non calcified/grey/fish flesh and type 1 85	
fully calcified in one eye (6%) only respectively. 86	
 87	
The natural history of CR was ascertained. Cavities collapsed ophthalmoscopy in 8 eyes 88	
(44%) after follow up of 18 (9, 2-48) months.  In 5 eyes with collapsed cavities the tumors 89	
were involving the fovea (28%), in 2 eyes cavitary tumors were present nasal to the disc and 90	
in one eye a cavitary tumor was superior to the disc. Out of 8 eyes with collapsed cavities 6 91	
eyes (75%) received adjuvant treatment for other non cavitary retinoblastoma and vitreous 92	
seeds (2-Plaque therapy, 2-Intra-arterial chemotherapy and 2-combined Cryotherapy/ 93	
Transpupillary thermotherapy/External beam radiotherapy). Reactivation of vitreous seeds in 94	
an eye with a solitary cavitary tumor was seen following systemic chemotherapy requiring 95	
enucleation; but there was no evidence of relapse of the cavitary tumor. Enucleation was 96	
required in another eye due to relapse of non-cavitary tumors. All 17 patients had at least 6 97	
months of follow-up; (100%), 7 patients have (42%) more than 3 years; and 3 (18.75%) more 98	
than 7 years of follow up. The mean follow-up period was 40 (35, 6–120) months. Overall, 99	
globe salvage was achieved in 16 eyes (89%). No metastasis or death occurred in any case. 100	
DISCUSSION: 101	
Retinoblastoma with small cavity was first documented in 1952 by Samuels and Fuchs with a 102	
suspicion that tumor liquefaction might in fact be a cyst.6 But the terms cavitary 103	
retinoblastoma for reference to this entity was first offered by Mashayekhi and coworkers 104	
because of the histopathologic absence of definite lining cells.2 Cavitary retinoblastoma is 105	
considered as a rare phenotype, 2.3% of patients.7  We found cavitary retinoblastoma in 6.8% 106	
of the newly diagnosed cases of retinoblastoma and this may be due to the fact that we have 107	
recorded cavities unveiled after chemotherapy, rather than on initial presentation, in nearly 108	
half of our patients. 109	
Lack of response has been observed with cavitary retinoblastoma, believed to be due to the 110	
presence of features of retinoma / retinocytoma (or well-differentiated retinoblastoma) within 111	
the mass.2,13,14  Retinoma is a benign, elevated, grey, translucent retinal mass with cottage 112	
cheese–like calcification and hyperpigmented retinal pigment epithelium. Histopathological 113	
features include abundant fleurettes and nonproliferative cells.15  114	
Retinomas can progress to retinoblastomas but when they present to the ophthalmologist, 115	
they are not treated but observed in case of progression. On presentation, they share 116	
similarities with treated CRs as they become malignant in only 10% of cases.16 117	
In 3 eyes (17%) laser (Transpupillary ThermoTherapy) was done where the tumor had 118	
regressed at mean follow up of 6 months. Consolidation was thought beneficial as the 119	
surgeon was unaware that the tumor was originally cavitary in nature and therefore bestowed 120	
with stability. All CRs (100%) remained stable at the mean follow up of 40 (35, 6–120) 121	
months.  122	
 123	
In our cohort we observed cavities collapsed in 2 eyes with systemic chemotherapy alone 124	
after follow up of 12 months and 20 months respectively while in the other 2 eyes, cavities 125	
collapsed after mean follow-up of 3 months where adjuvant treatment (laser, cryotherapy or 126	
IAC) was given to both cavitary & non cavitary tumors. Interestingly cavities in 4 eyes 127	
collapsed when the noncavitary tumors were treated with adjuvant measures (laser, IAC, 128	
brachytherapy) for relapse after mean follow up of 25 (25,2-48) months.  129	
Chemotherapy without additional laser can control 72% of retinoblastoma tumors (CR and 130	
non-CR). 5 However it is difficult to predict which tumors will relapse and which will not. As 131	
a result, many retinoblastoma surgeons treat all tumors with Type 2 and Type 3 regression 132	
with adjuvant therapy in order to create a flat scar. As CRs do not flatten on chemotherapy, 133	
this may involve multiple examinations under anaesthesia, large amounts of energy being 134	
applied to the eye and detrimental effects on visual function if the tumor is near the foveola. 135	
It is thought that eyes have been enucleated in the past as the surgeon was concerned about 136	
the lack of response of these tumors to chemotherapy. 137	
In this cohort, 15 of 18 cavitary tumors had no treatment after chemotherapy and did not 138	
relapse. Rojanaporn et al7 stated 4 of 26 tumors had no adjuvant treatment and did not 139	
relapse. 3 of 25 (12%) eyes did however relapse and required enucleation although only one 140	
had viable tumor on histopathology. In our cases two eyes were enucleated because of relapse 141	
in the noncavitary tumor or vitreous seeds (D eyes). We concur that these tumors do not 142	
require aggressive therapies following systemic chemotherapy. 143	
 Although of 250 patients, 67% were unilateral and 33% were bilateral, in CR cases, it was 144	
the reverse: 29% (5/17) were unilateral and 71 % (12/17) were bilateral.  This was also the 145	
case in Rojanaporn7 et al’s paper (33% unilateral, 67% bilateral).  As the majority of 146	
unilateral sporadic patients (80%) were enucleated, it is possible that some may have 147	
harboured CRs. Also, bilateral cases would have multiple tumor foci and there is a higher 148	
chance that one could evolve into a cavitary tumor. Germline (hereditary) mutations were 149	
identified in 82% (14/17) of CR patients (in all 12 bilateral patients as would be expected and 150	
2 unilateral patients).  4/14 (29%) of germline cases were mosaic for their RB1 mutations.  151	
This figure is higher than expected (8-10% of retinoblastoma germline cases are mosaic for 152	
their mutations - Z. Onadim unpublished laboratory data) but the sample size is small. The 153	
only other study to perform genetic testing7 found germline mutations in 11/24 (41%) 154	
patients. The higher detection rate may reflect recent innovations in uncovering mosaics. 155	
 156	
 157	
This paper adds credence to previous work that cavitary retinoblastoma tumors can be 158	
observed in a similar manner to retinomas/retinocytomas. The detection of cavities following 159	
chemotherapy has not been previously described. Although the numbers are small and some 160	
patients were treated with whole eye treatments, we concur that cavities confer stability to 161	
these tumors. 162	
 163	
STUDY LIMITATIONS 164	
As it is a retrospective study we were unable to acquire the pre and post treatment 165	
measurements of the cavities in the CRs via ultrasound. Neither could we perform further 166	
immunohistochemistry on the slides of the two enucleated eyes. We only included tumors 167	
with cavities that were visible superficially on presentation or became unmasked after 168	
chemotherapy. OCT scanning may be helpful in detecting cavities that are deeper and cannot 169	
be seen with an ophthalmoscope.     170	
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Figure	Legends	231	
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Figure	1.	Tumor	at	presentation:	no	superficial	cysts	present	236	
	237	
Figure	2.	Cysts	evident	after	2	cycles	of	systemic	chemotherapy	(Carboplatin,	Etoposide	and	238	
Vincristine)	239	
	240	
